Roots Analysis has done a detailed study on China Pharmaceutical Contract Manufacturing Services Market, 2020-2030, covering key aspects of the industry and identifying key future growth opportunities.
To order this 200+ page report, which features 85+ figures and 100+ tables, please visit this link
Key Market Insights
For more information, please visit https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html
Table of Contents
3.4.2. Modern CMOs
3.5. Services Offered by CMOs
3.6. Pharmaceutical Contract Manufacturing Scenario in China
3.7. Advantages and Challenges associated with Outsourcing Pharmaceutical Manufacturing to China-based CMOs
4.2.1. Comparison of General Characteristics
4.2.2. Comparison of Manufacturing Processes
4.2.3. Comparison of Key Manufacturing-related Challenges
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Product (API and FDF)
5.2.5. Analysis by Type of FDF
5.2.6. Analysis by Type of Packaging
5.2.7. Analysis by Manufacturing Facilities
5.3. Non-Chinese Pharmaceutical CMOs with Manufacturing Facilities in China: List of Companies
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters
5.3.4. Analysis by Type of Product (API and FDF)
5.3.5. Analysis by Type of FDF
5.3.6. Analysis by Type of Packaging
5.3.7 Analysis by Manufacturing Facilities
7.1. Chapter Overview
7.1.1. Health Authorities in China
7.1.2. Overview of Regulatory Guidelines in China
8.1. Chapter Overview
8.2. 2Y-Chem
8.2.1. Company Overview
8.2.2. Service Portfolio
8.2.3. China-based Manufacturing Facilities and Capabilities
8.2.4. Recent Developments and Future Outlook
8.3. Aurisco Pharmaceutical
8.3.1. Company Overview
8.3.2. Service Portfolio
8.3.3. China-based Manufacturing Facilities and Capabilities
8.3.4. Recent Developments and Future Outlook
8.4. ChemPartner
8.4.1. Company Overview
8.4.2. Service Portfolio
8.4.3. China-based Manufacturing Facilities and Capabilities
8.4.4. Recent Developments and Future Outlook
8.5. Dorrapharma
8.5.1. Company Overview
8.5.2. Service Portfolio
8.5.3. China-based Manufacturing Facilities and Capabilities
8.5.4. Recent Developments and Future Outlook
8.6. Hubei Biocause Pharmaceutical
8.6.1. Company Overview
8.6.2. Service Portfolio
8.6.3. China-based Manufacturing Facilities and Capabilities
8.6.4. Recent Developments and Future Outlook
8.7. &nb
- Pipelines are used in Ktor as an extension mechanism to plug functionality in at the right place. For example, a Ktor application defines five main phases: Setup, Monitoring, Features, Call and Fallba
- Form Builder APP is developed to make form creation process much easier! The subject of geography may perhaps be extremely
- We ensure you that if you give your time to our helping material and practice tests.
- Dua Artis Terciduk Sedang Berhubungan Intim dengan Pelanggan, Polisi Ungkap Kronologi Penangkapan ST dan MY bercumbu aw aw